News
EU approval for Rinvoq to treat atopic dermatitis
The European Commission (EC) has approved Abbvie’s JAK inhibitor Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.